|

Immunotherapy: adjuvant durvalumab Clinical Trials

1 actively recruiting trial

Top Sponsors

  • University Medical Center Groningen1

Indications

  • Carcinoma, Non-Small-Cell Lung1
  • Lung Cancer1
  • Cancer1

Other1 trial

IMPT Dose Escalation for NSCLC (HyDose)
N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.